Garth Cumberlidge, PhD, Chairman of the Board

Garth is currently President and CEO of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).

Frank Kalkbrenner, MD, PhD

Dr. Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim Corporate Venture Fund. Over the last years, he has been involved in several investments of the fund. He serves as Board member of STAT Diagnostica in Barcelona, Eyevensys in Paris, Hookipa Biotech in Vienna, and Acousia Therapeutics in Tübingen. Dr. Kalkbrenner is also a member of the Supervisory and the Advisory Board of Inserm Transfer Initiative, a French Seed Investment Fund based in Paris. Dr. Kalkbrenner studied medicine and holds a degree in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin. His academic research focused on gene regulation and signal transduction mediated by ion channels and G proteins.

Mrs Chahra Louafi

Chahra is the Investment Director and head of the fund for biotherapies and rare diseases at Bpifrance which she joined in 2001. She is also Vice-president of the Supervisory Board of Inserm Transfert Initiative and a member of the Supervisory Board of Cap Decisif Management. Previously she was in charge of project development and company inceptions in a private incubator for biotechnology companies. Chahra Louafi also sits on the Board of DBV Technologies, Sensorion, MedDay, Pixium Vision and Lysogene.

Mrs Catherine Boule

Catherine is a Partner at Cap Decisif, a Paris-based seed Fund, which she joined in 2003. She is also a Board Director at Axess Vision Technology, EyeBrain, Innavirvax, Eviagenics, Physikron, VitamFero, Laboratoire Watchfrog and Voluntis.

Mr. Ohad Hammer

Ohad has been a biotech analyst at Pontifax for 8 years. He is involved in identifying as well as evaluating new investment opportunities. Ohad focuses on early-stage projects and oversees scouting, due diligence and company formation. He also supports development and business development activities within Pontifax’s early-stage portfolio companies. Ohad obtained his M.S. in Biology from Tel-Aviv University and writes about small and mid-cap biotech stocks on his blog:

Mr. Fran├žois Thomas

François is Venture Partner at Sofimac Innovation, Paris. A medical oncologist by training, he has spent his career in exective management with big pharma and biotech in R&D , business development and executive management. He is a former partner at Atlas Ventures in London. In addition to Eyevensys, Dr. Thomas serves on a number of other boards, including Aelis Pharma, Biomodex, Inotrem, Sensorion and Step Pharma. 

Dr Francine Behar-Cohen, MD, Founder of Eyevensys

Francine founded Eyevensys in December 2008. From 2013 to 2016, she was the Chief Medical Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She is Professor of Ophthalmology at Paris Descartes University (France), Head of the Department of Ophthalmology of Hôtel-Dieu – University of Paris Descartes Hospital, and Director of the “Physiopathology of Ocular Diseases” lab at the Cordeliers INSERM Centre. She has authored over 164 publications since 1999. Very entrepreneurially oriented, Francine also founded Eyegate Pharma in 1997.